Voyager Therapeutics, Inc. (FRA:VT6)

Market Cap	204.86M -0.8%
Revenue (ttm)	34.39M -49.5%
Net Income	-101.97M
EPS	-1.74
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	174
Open	3.428
Previous Close	3.304
Day's Range	3.428 - 3.428
52-Week Range	2.218 - 4.872
Beta	n/a
RSI	52.07
Earnings Date	May 8, 2026

About Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease. The company also provides research program for the treatment of Huntington’s disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small mo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 141
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: VT6

Financial Performance

In 2025, Voyager Therapeutics's revenue was $40.37 million, a decrease of -49.53% compared to the previous year's $80.00 million. Losses were -$119.72 million, 84.2% more than in 2024.

Financial numbers in USD